Study shows abiraterone acetate is useful even in most aggressive prostate cancers

(University of Colorado Anschutz Medical Campus) In study of nearly 2,000 prostate cancer patients, treatment with the androgen-lowering drug abiraterone acetate (Zytiga) led to longer overall disease control, even when a very high Gleason score indicated especially aggressive cancer.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news